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ABSTRACT 
Sequencing of mba gene fragments of reference strains of Ureaplasma
urealyticum serovars 1, 3, 6, 14, in addition to 33 clinical U.  urealyticum isolates
is reported.  A phylogenetic tree deduced from an alignment of these sequences 
clearly demonstrates two major clusters (confidence limit 100%), which equate 
to the parvo and T960 biovars, and five types which we have designated mba 1, 
3, 6, 8 and X.  These relationships are supported by bootstrap analysis.  
Polymorphisms within the mba fragment of types mba 1, 3, and 6 were used to 
define nine subtypes (mba 1a, 1b, 3a, 3b, 3c, 3d, 3e, 6a, and 6b) thus facilitating 
high resolution typing of U.  urealyticum.  Inclusion of the reference strains for 
serovars 1, 3, 6, and 8 in the mba typing scheme showed that the results of this 
analysis are broadly consistent with currently accepted serotyping.  In addition a 
ure gene fragment from nine of the clinical isolates was amplified and 
sequenced. Comparisons of the sequences clearly distinguished the two biovars 
of U.  urealyticum; however this fragment was invariant within the parvo biovar.  
This study has shown that the sequence of the mba can reveal the fine details 
of the relationships between U.  urealyticum isolates and also supports the 
significant evolutionary gap between the two biovars. 
KEYWORDS
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INTRODUCTION     
Members of the class Mollicutes are small, free living, wall-less procaryotes 
which are characterised by small genomes with a low G+C content and unusual 
nutritional requirements (20).  The largest family within the Mollicutes is the 
Mycoplasmataceae of which both the mycoplasmas and the ureaplasmas are 
members. The ureaplasmas are distinguished phenotypically by their ability to 
hydrolyse urea (30).  
The phylogeny of the Mollicutes, the genus Ureaplasma, and the species
urealyticum has been defined by comparison of 16S rRNA gene sequences (10, 
15, 23, 32, 38).  There are five phylogenetic groups within the Mollicutes and the 
ureaplasmas belong to the M.  pneumoniae - Ureaplasma  clade (15, 38).  Six, 
phylogenetically distinct ureaplasma species, each isolated from a different host 
(humans and five different animals) have been defined (10, 32).  Ureaplasmas 
isolated from humans are currently classified as a single species U. urealyticum.
However strains within this species can  be clearly separated into  two biovars 
by a variety of techniques including 16S rRNA sequencing (23).  Other methods 
which have been used to distinguish the biovars of U.  urealyticum include: 
DNA-DNA hybridisation (5), restriction endonuclease cleavage patterns (21), 
RFLP analysis (11), one- and two- dimensional gel electrophoresis of cell 
proteins (16, 33), genome size as determined by PFGE (24), sensitivity to 
manganese salts (22) and enzyme profiles (6).  More recently  the biovars have 
also been distinguished by: PCR of the 16S rRNA gene (27); PCR of the 
Multiple Banded (MB) antigen gene (mba) (34); and by arbitrarily primed PCR 
(8, 9, 13). 
Whilst the biovar grouping is easily determined the subgroups within these 
biovars are less well defined.  U.  ureaplasma strains are most commonly 
identified by serotyping. The parvo biovar (biovar 1) contains serovars 1, 3, 6, 
and 14 and the T960 biovar (biovar 2) contains serovars 2, 4, 5, and 7-13. There 
are a number of different serotyping techniques (14, 17, 19, 25, 26, 31).  
However these are difficult to perform since there are no  commercially available 
antisera.  
Apart from 16S rRNA comparisons, the two biovars have rarely been 
distinguished by direct gene sequencing since very few U.  urealyticum  genes 
have been characterised.  Polymorphisms which differentiate the two biovars 
have, however, been detected in the urease gene (ure) (2, 18), and recently the 
mba gene of serovars 3 and 14 have been compared (41).   Whilst the 
phylogeny of the ureaplasmas has been broadly defined using 16S rRNA (10, 
15, 23) it has not been supported by detailed analysis of other gene loci. 
Therefore the main objective of the present study was to determine the 
relationships between U.  urealyticum reference serovars and clinical isolates by 
sequence analysis of gene fragments which are more likely to be polymorphic 
than the 16S rRNA.  Two fragments were used in this study: (i) the 5’ end and 
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the upstream control region of the mba gene, and  (ii) an internal fragment of the 
ure gene.
MATERIALS AND METHODS 
Samples
U.  urealyticum isolates used were: (i) the reference serovars (1, 3, 6, 14, and 8) 
which were provided by G.  L.  Gilbert (University of Sydney, Sydney, Australia), 
with the kind permission of H.  L.  Watson (University of Alabama, Birmingham, 
AL, USA). [Serovars 1, 3, 6 and 8 were originally obtained from E.  A.  Freundt 
(Institute of Medical Microbiology, University of Aarhus, Denmark) and serovar 
14 from J.  A.  Robertson (Department of Medical Microbiology and Infectious 
Diseases, University of Alberta, Canada)]; and (ii) 33 clinical samples from 
pregnant women, collected during a previous clinical study (12).  All 
ureaplasmas were cultured and stored as previously described (12) using A8 
agar medium (modified) (Becton Dickinson, Brisbane, Australia) and Shepard’s 
U9B and U10B liquid broth (30, 31).   
DNA preparation  
Ureaplasma DNA was prepared by one of three methods: (i) Initially stored 
clinical samples of U.  urealyticum were thawed and subcultured in 1.8 mL 10B 
broth and incubated at 37 0C until an alkaline colour change was observed.  
Broths were boiled for 20 minutes, then centrifuged for 5 minutes at 15 000 x g 
(Beckman Microfuge E). The supernatant was collected and then used for mba
gene PCR. More recently we have used another previously described method 
(3) with greater success, i.e. (ii) Stored clinical samples (U9B broth) of U.
urealyticum were thawed and 250 L of the sample was centrifuged at 15,900 x 
g (Beckman Microfuge E) for 20 min at 4 0C.  The pellet was resuspended in 50 
L of Solution A (10 mM Tris HCl pH 8.3, 100 mM KCl, 2.5 mM MgCl2) and 50 
L Solution B (10 mM Tris HCl pH 8.3,  2.5 mM MgCl2, 1% Tween 20, 1% Triton  
X-100) with 120 g/mL of proteinase K. The suspension was incubated for 1 
hour at 60 0C, then 10 min at 94 0C . It was then cooled and 5 L of each 
sample was used for mba gene PCR or stored at -20 0C until PCR analysis.  (iii) 
Stored clinical samples and the reference strain serovars 1, 3, 6, 14 and 8,  
were inoculated into 25 mL of 10B broth  and incubated at 37 0C until an alkaline 
colour change was observed.   The broth was then centrifuged at 24,000 x g 
(Beckman J2-21M/E) for 1 hour.  The pellet was washed in 2 mL of cold TE 
buffer and re-centrifuged for 15 mins at 15,900 x g ( Beckman Microfuge E) at 4 
0C. The pellet was resuspended in equal volumes (250 L) of  Solution A and 
Solution B with 120 g/mL of proteinase K and then incubated for 1 hour at 60 
0C.  Samples were cooled and the DNA was extracted (36) with equal volumes 
of (a) phenol, (b) phenol/chloroform/isoamyl alcohol (25:24:1, vol/vol/vol), and 
(c) chloroform/isoamyl alcohol (24:1, vol/vol) and then precipitated from the 
aqueous phase with 0.1 volume of 3 M sodium acetate (pH 5.2) and 2 volumes 
of ethanol.  The DNA pellet was resuspended in 25 L of water. 
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mba Gene PCR and sequencing 
Primers
The primers used in this study were derived from the published nucleotide 
sequence of the serovar 3 mba gene (34).  This gene codes a surface exposed 
protein (MB) and contains a 5’, 450 bp region plus a 3’ region from position 451 -
1206 of identical 18 nucleotide repeats (40).  Primers UMS-125 (5’-
GTATTTGCAATCTTTATATGTTTTCG-3’) and UMA226 (5’-CAGCTGATGTA-
AGTGCAGCATTAAATTC-3’) (34) were selected to amplify  the 5’ region from  
position -150 to 253 (serovar 3) which  produced a 403 or 404  bp product for 
parvo biovar isolates and a 448 bp product for biovar T960 isolates. 
PCR conditions  
The 50 L reaction mixture contained 1U of Taq polymerase (Boehringer 
Mannheim), 10x PCR buffer (100 mM Tris HCl, 15 mM MgCl2, 500 mM KCl, pH 
8.3, Boehringer Mannheim), 200 M of each deoxynucleotide triphosphate 
(Boehringer Mannheim), water, 0.25 M of each primer and DNA template (5 L
of prepared clinical specimen or 1 L of extracted DNA).  Amplification was 
performed in a thermal cycler (Perkin-Elmer) programmed for 35 cycles-
denaturation at 94 0C for  30 s, annealing at 55 0C for 1 min and extension at 72 
0C for 1min, followed by a final cycle of 72 0C for 5 min.  
DNA sequencing   
The PCR products were  separated by electrophoresis in a 1% (w/v) low-
melting-point agarose gel and the mba gene product excised and purified using 
a Wizard PCR Preps DNA Purification System (Promega).  Nucleotide 
sequencing was performed using the dideoxy method (29) using an Applied 
Biosystems 373A DNA sequencer (Perkin Elmer, Cetus).  The products were 
sequenced in both directions using the forward (UMS-125) and reverse 
(UMA226) primers and repeat PCR and repeat sequencing were performed until 
all anomalies were resolved.  All nucleotide sequences were first edited to a 310 
or 311bp fragment (parvo biovar) or a 315 bp fragment (biovar T960) and then 
aligned with the U.  urealyticum mba gene sequence of the serovar 3 reference 
strain, GenBank accession number L20329 (40),  using Clustal W (35). 
Urease Gene PCR and sequencing 
Primers   
For the amplification of the urease gene we used the previously published (39) 
primers 14b, (5’-CCAGGTAAATTAGTACCAGG-3’-sense) and 72c, (5’-
CCTAATCTAACGCTATCACC-3’-antisense) to produce a 458 bp product which 
84
encodes a region of the gene incorporating the C-terminal region of the 
subunit (14 kD) of urease, a 58 bp intergenic region and the N-terminal region of 
the  subunit (72 kD) of urease. 
PCR Conditions   
This PCR reaction was performed in a total volume of 50 L and the mixture 
contained 1 U of Taq polymerase (Boehringer Mannheim), 10x PCR buffer (100 
mM Tris HCl, 15 mM MgCl2, 500 mM KCl, pH 8.3, Boehringer Mannheim), 400 
M of each deoxynucleotide triphosphate (Boehringer Mannheim), water, 20 
pmol of each primer and DNA template (1 L of extracted DNA).  The thermal 
cycler (Perkin-Elmer) was programmed for 35 cycles - denaturation at 94 0C for 
30 s, annealing at 55 0C for 1 min and extension at 72 0C for 1 min, followed by 
a final cycle of 72 0C for 5 min.  The PCR products were purified for sequencing 
as described for the mba gene. The nucleotide sequences were edited to a 389 
bp fragment and aligned with three U.  urealyticum urease gene sequences, 
Genbank accession numbers: X51315 (2),  M36190 (39) and L40489 (18) using 
Clustal W (35).  
Phylogenetic analysis 
Sequence homology was compared and a distance matrix generated using 
Phylip (version 3.5) (7).  The distance matrix was then used to construct an 
unrooted phylogenetic tree using the neighbour-joining (NJ) method (28).  
Confidence limits on branching orders were tested using bootstrap analysis (7) 
using the  NJ and bootstrap applications in Clustal W (35). 
RESULTS 
mba gene sequencing identifies 11 subtypes of U.  urealyticum 
mba gene fragments were amplified from the five reference serovars tested and 
33 clinical samples.  The reference serovars 1, 3, 6 and 14, and 31 of the clinical 
samples produced a 403 or 404 bp fragment,  whereas serovar 8 and the other 
two clinical  isolates produced a 448 bp fragment.  Alignment of these 38 mba
gene sequences identified 11 U.  urealyticum subtypes which on the basis of 
their sequence similarities and amplified fragment sizes could be separated into 
two major clusters.  The phylogenetic tree deduced from this alignment clearly 
demonstrated these clusters as two widely separated branches (confidence limit 
100%) which equate to the parvo biovar and the T960 biovar of U.  urealyticum 
(Figs 1 and 2).  
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                         -  -104                                                                  -35             -47
mba 3a,(serovar 3)  CTGTAGAAATTATGTAAGATTACCAAATCT.TAGTGTTCATATTTTTTACATATATTAAA 
mba 3b              ------------------------------.----------------------------- 
mba 3c              ------------------------------.----------------------------- 
mba 3d             ------------------------------.C---------------------------- 
serovar 14(mba 3e)  ----------------------AT------.----------------------------- 
mba 1a,(serovar 1)  ---------------------G-T------.--------------------C-------- 
mba 1b              ---------------------G-T------.--------------------C-------- 
mba 6a,(serovar 6)  --A—-A----------------AT------.-------------------TAG------- 
mba 6b              --A--A----------------AT------.-------------------TAG------- 
mba 8a,(serovar 8)  A-C--T-C---C-.A----AA-AT-T-—T-GC-AAAC-ATA-A-AGAC---A—A-AC--T 
mba X               A-C—-T—C---C-.A----AA-AT-T—-T-GC-AAAC-ATA-A-AGAC---A-A-AC--T 
                                                -10                                 RBS                Signal peptide 9
mba 3a,(serovar 3)  T.AAAAACAATA..AAATGACATATTTTTTATATTAGGAGAA..TCATAAATGAAATTAT
mba 3b              -.----------..----------------------------..---------------- 
mba 3c              -.----------..----------------------------..---------------- 
mba 3d              -.----------..----------------------------..---------------- 
serovar 14(mba 3e)  -.----------..----------------------------..---------------- 
mba 1a (serovar 1)  -.---G------..----------------------------..---------------- 
mba 1b              -.---G------..----------------------------..---------------- 
mba 6a (serovar 6)  -T----------..----------------------------..C--------------- 
mba 6b              -T---G------..----------------------------..C--------------- 
mba 8a (serovar 8)  AG—-T--T—-A-CT----TT-------AG-T----------TCG-T-------------- 
mba X               AG-—T—-T—-A-CT----TT-G-----AG-T----------TCG-T-------------- 
                                                                                                                     69
mba 3a,(serovar 3)  TAAAAAATAAAAAATTCTGAGCTATGACATTAGGTGTTACCTTAGTTGGAGCTGGAATAG
mba 3b              --------------------------------------------A--------------- 
mba 3c              ------------------------------------------------------------ 
mba 3d              ------------------------------------------------------------ 
serovar 14(mba 3e)  ------------------T----------------------------------------- 
mba 1a,(serovar 1)  ----------------------------------A------------------------- 
mba 1b              ----------------------------------A------------------------- 
mba 6a,(serovar 6)  ----------------------------------A------------------------- 
mba 6b              ----------------------------------A------------------------- 
mba 8a,(serovar 8)  ----------G-----T-G---A—-T---C----G—-A—-T-----G-----A—-GG--- 
mba X               ----------G-TT—-T-G---A-—A---C----G—-A—-T-----G-----A—-GG--- 
                                                      Mature protein                                              129
mba 3a,(serovar 3)  TTGCTATAGCAGCTTCATGTTCTAATTCAACTGTTAAATCTAAGTTAAGTAACCAATTTG 
mba 3b              ------------------------------------------------------------ 
mba 3c              ------------------------------------------------------------ 
mba 3d              ------------------------------------------------------------ 
serovar 14(mba 3e)  ------------------------------------------------------------ 
mba 1a              -------------------------------C-----------A---------------- 
mba 1b              -------------------------------C-----------AC--------------- 
mba 6a              ----------G----------------------------------------G-------- 
mba 6b              ----------G----------------------------------------G-------- 
mba 8a,(serovar 8)  -----G-G—---------------GC----A------------A-------GT---C--- 
mba  X              -----G-G—---------------GC----A------------A-------GT---C--- 
                                                                                                                    189
mba 3a,(serovar 3)  CTAAATCAACAGACGGTAAAAGTTTTTATGCGGTTTACGAAATTGAAAACTTTAAAGATC 
mba 3b              ------------------------------------------------------------ 
mba 3c              -----------------------------------------------C------------ 
mba 3d              ------------------------------------------------------------ 
serovar 14(mba 3e)  ------------------------------------------------------------ 
mba 1a,(serovar 1)  ---------------A-------------------------------------------- 
mba 1b              ---------------A-------------------------------------------- 
mba 6a (serovar 6)  T------------T-A---------------A---------------------------- 
mba 6b              T------------T-A---------------A---------------------------- 
mba 8a,(serovar 8)  T--------A-----AA—-G-—C-----C—-T--------C--------T—-CG-T---T 
mba X               T--------A-----AA—-G—-C-----C-—T--------C--------T-—CG-T---T 
                                                  207
mba 3a,(serovar 3)  TAAGTAATGATGATAA 
mba 3b              ---------------- 
mba 3c              ---------------- 
mba 3d             -----G---------T 
serovar 14(mba 3e)  ---------------- 
mba 1a (serovar 1)  -----G—-A------- 
mba 1b              -----G—-A------- 
mba 6a,(serovar 6)  -----G—-A------- 
mba 6b              -----G—-A------- 
mba 8a,(serovar 8)  ---C-G-AA------- 
mba X               ---A-G-AA------T 
FIG.  1.  Nucleotide sequence alignment of the mba  fragments of the mba
subtypes and the reference serovars 1, 3, 6, 8 and 14.  A dash indicates that the 
position in the alignment is conserved.  The dots indicate spaces between 
adjacent nucleotides introduced for maximum alignment.  The underlined areas 
are the predicted promoter consensus site, the ribosomal binding site (RBS) and 
the signal sequence (41). 
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Within the parvo biovar there are three major clusters which we have designated 
as  mba 1, 3 and 6.  These distinct types are supported by:  (i) the confidence 
limits of the branching order, mba 1 (confidence limit 98.4%), mba 3 (95.9%), 
and mba 6 (98.9%) (Fig. 2) as determined by bootstrapping and; (ii) the 
similarity matrix (Table 2) which shows that the isolates within each of these 
types exhibit an homology of 98% whilst the homology between these types is 
<97%.  Using this criteria and to minimise subjectivity, an mba type has been 
arbitrarily defined in this study as U.  urealyticum strains with 98% homology.  
A workable nomenclature has also been devised from these data that is as 
consistent as practicable with serotyping. 
FIG.  2.  Phylogenetic tree of U.  urealyticum based in the Clustal W alignment 
of the mba gene fragment of the reference serovars 1, 3, 6, 14, and 8 and 33 
clinical isolates.  Bootstrap percentage values were obtained from 1000 
resamplings.
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Consequently, each mba type has been numbered according to the serovar that 
is found within the cluster (Fig. 2). The reference serovar 1 and eight clinical 
isolates were identified as type mba 1; type mba 6 contains the reference 
serovar 6 and six clinical isolates.  The third cluster contained two reference 
serovars (3 and 14) as well as 17 clinical  isolates.  However, since the 
sequence identical to serovar 3 was detected most frequently in this study we 
designated this cluster as type mba 3.  
The mba types 1, 3 and 6 (parvo biovar) could be further subdivided into eight 
subtypes (Table 1) (Fig. 1).  Within type mba 3 there were four subtypes (mba
3a, 3b, 3c, 3d).  Mba subtypes 3b and 3c each differed from mba 3a by only a 
single bp change.  However there were 3 bp differences between mba 3a and 
mba 3d.  The sequence of subtype mba 3a is identical  to the reference strain 
serovar 3 and the published sequence of serovar 3 (40).  In this study serovar 
14 was classified as an mba 3 subtype (mba 3e)  rather than as a separate type 
since there are only 3 bp differences between serovar 14 and type mba 3a 
which equates to an homology of 99% (Table 2).  Within type mba 1 there were 
two subtypes (mba 1a and 1b) which differed by only a single bp change.  
Similarly there were two mba 6 subtypes that differed by only a single bp 
change.   
TABLE 1.  Comparison of mba and ure typing schemes with previous subtyping 
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TABLE 2.  Similarity matrix of the mba subtypes of U.  urealyticum based on the 
mba fragment sequence comparisons. 























mba1a            
mba 1b 99           
mba 3a 96 96          
mba 3b 96 96 99         
mba 3c 96 96 99 99        
mba 3d 96 96 99 98 98       
mba 3e 96 96 99 98 98 98      
mba 6a 94 94 94 94 94 94 94     
mba 6b 95 94 94 93 93 93 94 99    
mba 8 74 74 73 73 73 73 74 74 74   
mba x 73 72 72 71 71 72 72 72 72 97  
            
The two, T960 biovar isolates studied were identified as two separate types,  
mba 8 and mba X using the same criteria.  These two isolates differed from 
each other by 6 bp with an homology of only 97% (Table 2).  The mba
sequences of mba 1a, mba 6a and mba 8 are identical to those of the reference 
serovars 1, 6 and 8 respectively.  Since a serovar with  98%  similarity to mba
X has not yet been identified, this separate designation has been used. 
Urease Gene Analysis 
A fragment of the ure gene was also sequenced to confirm the phylogenetic 
groupings within the U.  urealyticum species.  Partial urease sequences (Fig. 3) 
were generated for nine clinical isolates (eight parvo biovar isolates and one 
T960 biovar isolate).  These were aligned and compared with the three available 
sequences in Genbank: Genbank Accession No. X51315 (2) and Genbank 
Accession No. M36190 (39), both serotype 8 U.  urealyticum; and Genbank 
Accession No.  L40489 (18), a serotype 1 U.  urealyticum.  Of the nine clinical 
isolates studied,  eight isolates (of the parvo biovar) had sequences identical to 
that of serotype 1 (L40489) U.  urealyticum (ure I).  These eight parvo biovar 
isolates represented mba subtypes 3a, 3b, 1a, 1b, and 6a (Table 1).  
.
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                                                585      subunit         612 
Serovar 1(strain 7  Genbank Accession No L40489)AAATTGTGATGAATGAAGGTAGAGAGGC
Parvo biovar, 8 clinical isolates (this study)------------------------------ 
Serovar 8 (UUUREASE Genbank Accession No.X51315)-------------C-----------A-- 
Serovar 8 (URELOCAB Genbank Accession No.36190)----A---------C-----------A-- 
Biovar T960, 1 clinical isolate-(this study)-----------------C-----------A-- 
                                                                          672 
serovar 1       AAAAGTAATTAGTATTAAAAATACTGGGGACCGTCCTATACAAGTTGGATCACATTTTCA
8 isolates      ------------------------------------------------------------ 
Serovar 8       ---------C--C--------------T-----------C-----------------C-- 
Serovar 8       ---------C--C--------------T-----------C-----------------G-- 
1 isolate       ---------C--C--------------T-----------C-----------------C-- 
                                                                          732 
serovar 1       CTTGTTTGAAGTGAATAGTGCATTAGTATTTTTTGATGAAAAAGGAAATGAAGATAAAGA
8 isolates      ------------------------------------------------------------ 
serovar 8       ---A------ACA-----------------C-----------------C-----C----- 
serovar 8       ---A------ACA-----------------C-----------------C-----C----- 
1 isolate       ---A------ACA-----------------C-----------------C-----C----- 
                                                                          792 
serovar 1       ACGCAAAGTTGCTTATGGACGACGTTTCGATATTCCATCAGGTACTGCTATTCGTTTTGA
8 isolates      ------------------------------------------------------------ 
serovar 8       ---T-----------------T-------------------------------------- 
serovar 8       ---T-----------------T-------------..----.------------------ 
1 isolate       ---T-----------------T-------------------------------------- 
                                                                          852 
serovar 1       ACCAGGAGATAAAAAAGAAGTTTCAATTATTGATTTAGCCGGAACACGC.GAAGTTTGAG
8 isolates      -------------------------------------------------.---------- 
serovar 8       ---------C---------------G------------T---------TT---------- 
serovar 8       ---------C---------------G------------T---------TT---------- 
1 isolate       ---------C---------------G------------T---------T.---------- 
                              868                                         905 
serovar 1       GTGTAAATGGCTTAGTTAATGGAAAA..CTTAAAAAATAAAACTCTATTTTACAAGTTTC 
8 isolates      --------------------------..-------------------------------- 
serovar 8       -------C-----------C------..-----------....-------.--------- 
serovar 8       -------C-----------C--C---AC------------...-------.--------- 
1 isolate       -------C-----------C--C---..------------...-------.--------- 
                                           subunit                     962 
serovar 1       TACTATAGATAAAAAGGGGAACATTATGTTTAAAATTTCAAGAAAAAATTATTCAGATTT
8 isolates      ------------------------------------------------------------ 
serovar 8       ---------CG--..------------------------------------C------C- 
serovar 8       ---------CG--..------------------------------------C------C- 
1 isolate       ---------CG--..------------------------------------C------C- 
                  965 
serovar 1       ATA
8 isolates      --- 
serovar 8       --- 
serovar 8       --- 
1 isolate       --- 
FIG. 3.  Sequence alignment of the ure gene of serovars 1 (ure I) and 8 (ure II) 
and the ure fragments of nine clinical isolates of U. urealyticum.  A dash 
indicates that the position in the alignment is conserved.  The dots indicate 
spaces between adjacent nucleotides introduced for maximum alignment.  The 
underlined areas are the beta and alpha subunits (2). 
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The sequence of the remaining clinical isolate (a T960 biovar isolate, type mba
8) differed from the previously published sequences of two different strains of 
serovar 8 Genbank Accession Nos:  X51315 (by 3 bp differences), and;  
M36190 (by 8 bp differences) both of T960 biovar (ure II).  Small differences 
within this fragment in the T960 biovar have previously been reported (39). 
Despite sequencing only a single T960 biovar isolate these results also clearly 
demonstrate the two clusters of U.  urealyticum (Table 1) since there were 28 bp 
differences between the parvo and T 960 biovar isolates. 
DISCUSSION
The detection and typing of U.  urealyticum has always been difficult.  Culture is
expensive and time-consuming and, whilst still used routinely, more efficient 
alternatives are needed.  Previously U.  urealyticum  has been subtyped into 14 
serovars by serotyping (4) however results may be conflicting due to cross 
reactivity and also the common expression of epitopes (4), a problem which is 
exacerbated by the lack of standardised reagents and methods.  Serotyping of 
clinical isolates is particularly difficult since techniques often require the culture 
of primary isolates prior to serotyping making it difficult to detect serovars 
present in lower concentrations and those that are more fastidious and grow 
more slowly (4, 19).  The immunoperoxidase assay (19) and the modified 
indirect immunofluorescence test (17) can both be performed on ureaplasma 
primary isolation plates however again there are no standardised procedures or 
commercially available products.  More recently DNA based typing approaches 
have been used with some success (1, 8, 9, 13, 34). 
Robertson et al. (1994) (23) have previously described the relationship between 
different serovars of U.  urealyticum. Analysis of a 1422-1430 base region of 
the 16S rRNA showed clear but minor (98.5-98.9% homology) differentiation of 
the two biovars of U.  urealyticum (23). Furthermore, within each biovar the 
serovars (serovars 2, 5, and 8, T906 biovar; serovars 1, 3, 6 and 14, parvo 
biovar) could be distinguished on the basis of  seven polymorphic base 
positions.  However this study did not confirm these relationships using a 
bootstrap analysis. 
In the current study, direct sequencing of the mba and the ure gene fragments 
was used to reveal the relationship between U.  urealyticum strains.  The mba
gene was selected for sequencing since the MB antigen, the predominant 
antigen recognised in human ureaplasma infections (37) is present in all 
reference serovars of U.  urealyticum (34) and since variation in this gene is 
thought to account for antigenic variation within the species and therefore may 
be the basis of the current typing schemes (40).  Furthermore the mba gene has 
previously been shown to be variable, with biovar specificity residing in the 5’ 
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region (34).  Sequencing of the mba fragments and upstream regions identified 
sufficient polymorphic base positions for subtyping of U. urealyticum and to give 
significance to phylogenetic branching orders.  Analysis of the deduced
phylogenetic tree shows two major groups which represent the two U.
urealyticum biovars (71-74% homology) (Table 2). Within these two biovars five 
types (mba 1, 3, 6, 8 and X, homology 98%) are also clearly distinguished, and 
confirmed by the confidence limits on the branching order.  Direct sequencing of 
the mba gene fragment has further elucidated the relationship between strains 
of U.  urealyticum and produced a subtyping technique with higher resolution 
than other methods previously used for the detection and typing of U.
urealyticum.  Inclusion of the four reference serovars (1, 3, 6, and 8 ) in the mba
typing scheme shows that it is broadly consistent with currently accepted 
serotyping.  However the scheme has also revealed an inconsistency.  Using 
serotyping and 16S rRNA analysis serovar 14 (Table 1) is identified as a 
separate type, whereas using mba subtyping serovar 14 is classified as a 
subtype of  mba 3. Presently mba subtyping defines the two biovars,  five mba
types and nine mba subtypes of U.  urealyticum.  However it could be extended 
with further analysis of clinical isolates and other reference serovars of U.
urealyticum.
Recently ureaplasmas have been detected by PCR in clinical specimens and 
broadly grouped into two clusters (1, 13).  While biotyping is easier to perform 
than serotyping it does not differentiate the strains sufficiently and is therefore of 
limited value in epidemiological studies. In contrast, mba subtyping is a readily 
reproducible molecular method, and since it can be used to detect and type U.
urealyticum in both cultures and original clinical specimens it will be more useful 
for epidemiological studies.  Furthermore, by exploiting the polymorphic base 
positions in the mba fragment it should be possible to design primers which will 
selectively amplify all mba  types directly from clinical specimens and potentially 
reveal mixed types.      
Direct sequencing of the ure gene fragment of nine clinical isolates also 
distinguished the two genomic clusters of U.  urealyticum.   Our results suggest 
that selection for conservation is greater in the ure gene fragment than in the 
mba gene fragment as there is no variation within the fragment within the parvo 
biovar.   Consequently, subtyping based on the mba gene fragment is more 
meaningful and will be more useful for the investigation of the relative 
pathogenicity of different strains of U.  urealyticum. 
U.  urealyticum can now clearly be differentiated into two biovars by a variety of 
typing techniques (Table 1) including: PCR of the mba gene and 16S rRNA; and 
sequence analysis of 16S rRNA.  Direct sequencing of both the mba and ure
gene fragments detected only small differences within the biovars and much 
larger differences in sequence between the biovars.  This is further evidence to 
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